Gene vectors derived from adeno-associated viruses (AAVs) are gaining strong momentum for in vivo applications, where efficient and long-term gene transfer is required and can be achieved by direct injection (Mueller and Flotte, 2008; Simonelli et at, 2010). Along with rapid expansion of the AAV toolbox, to which has been added novel natural serotypes and engineered capsids (Vandenberghe et al., 2009), the list of laboratories and publications using AAV is growing rapidly. Recombinant AAV has now become indisputably the most versatile in vivo gene delivery tool, not only for disease gene therapy but also for functional genomics and animal model development. Driven by the high demand, numerous new methods for large-scale vector production and purification have been made available (Zhang et ah, 2009). However, the devil is in the details. For researchers without prior experience and for studies that require large number of different vectors at a time, those details are still a significant issue.
展开▼
